Companies · India
Dishman secures commercial contract following US macrocyclic peptide launch
TideMetrix TakeDishman's first commercial contract at its Naroda facility following the approval of a macrocyclic peptide drug marks an important step in establishing its presence in the commercial peptide supply chain.
India's Dishman Carbogen Amcis has secured its first commercial contract at its Naroda operation linked to a macrocyclic peptide drug following the product's US approval in July.
Speaking during a November 16 earnings call, in a transcript filed on November 20, management said manufacturing activities at Naroda had supported the product's US launch.
Management also revealed that another major pharmaceutical company had approached Dishman for similar manufacturing services, pointing to potential further business opportunities in the sector.
The company did not disclose the identity of the drug, the customer or the specific material being manufactured at Naroda. Contract value and production volumes were also undisclosed.